Diabetes-related end-organ complications have in large part been attributed to glucose-induced activation of neurohormones and proinflammatory and profibrotic factors. Unfortunately, and in contrast to type 1 diabetes, individual pivotal trials examining the effect of intensive glycemic control in patients with type 2 diabetes have largely failed to demonstrate cardiovascular benefit or have even suggested harm.1 Although the mechanisms responsible for this lack of cardiovascular benefit are unknown, beneficial effects of the antihyperglycemic agent empagliflozin, a member of the sodium-glucose cotransport 2 (SGLT2) inhibitor class, were recently reported in the EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes) trial.